Drug Profile
Sitagliptin/pioglitazone - Merck & co
Alternative Names: Janacti; MK-0431C; Pioglitazine/sitagliptinLatest Information Update: 01 Sep 2014
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics; Pyrazines; Small molecules; Thiazolidinediones; Triazoles
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
- 14 Nov 2011 Regulatory submission withdrawn for Type-2 diabetes mellitus in European Union (PO)